上海醫藥(02607.HK)旗下高血壓藥上市許可申請獲受理

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

上海醫藥(02607.HK)旗下高血壓藥上市許可申請獲受理

阿思達克 06-19 17:27

上海醫藥(02607.HK)公布，全資子公司上藥信誼收到國家藥監局下發的《受理通知書》，公司提交的SPH3127片的藥品上市許可申請獲國家藥監局受理。 SPH3127片是新一代口服非(月太)類小分子腎素抑制劑，適用於原發性高血壓的治療。截止目前為至，SPH3127片相關項目累計已投入研發費用約2.88億元人民幣。

上海醫藥(02607.HK)

Relevant Stocks

上海醫藥(02607.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

上海醫藥(02607.HK)旗下高血壓藥上市許可申請獲受理

Services

About Us

Agreement Statement